• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

TNX-1800（一种活病毒重组痘病毒候选疫苗）在非人灵长类动物中针对新冠病毒攻击的免疫原性和效力

Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates.

作者信息

Awasthi Mayanka, Macaluso Anthony, Myscofski Dawn, Prigge Jon, Koide Fusataka, Noyce Ryan S, Fogarty Siobhan, Stillwell Helen, Goebel Scott J, Daugherty Bruce, Nasar Farooq, Bavari Sina, Lederman Seth

机构信息

Tonix Pharmaceuticals, Frederick, MD 21701, USA.

BioQual, Rockville, MD 20850, USA.

出版信息

Vaccines (Basel). 2023 Nov 2;11(11):1682. doi: 10.3390/vaccines11111682.

DOI:10.3390/vaccines11111682
PMID:38006014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10674175/
Abstract

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.

摘要

TNX-1800是一种人工合成的活重组嵌合马痘病毒（rcHPXV）候选疫苗，可表达武汉新冠病毒刺突（S）蛋白。本研究的主要目的是评估TNX-1800在两种受到美国WA1/2020新冠病毒攻击的非人类灵长类动物中的免疫原性和效力。TNX-1800疫苗接种耐受性良好，无严重不良事件，临床参数也无显著变化。通过抗新冠病毒S IgG的总结合以及针对美国WA1/2020毒株的中和抗体滴度测定，单剂量TNX-1800在非洲绿猴和食蟹猕猴中产生了体液反应。此外，单剂量TNX-1800在食蟹猕猴中诱导了干扰素-γ（IFN-γ）介导的T细胞反应。在用新冠病毒攻击后，非洲绿猴和食蟹猕猴在上呼吸道和下呼吸道均表现出病毒的快速清除。未来的研究将评估TNX-1800对新出现变异株的效力，并证明其在人类中的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/668765f5a161/vaccines-11-01682-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/412c2a0c228f/vaccines-11-01682-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/cc99b7f4a949/vaccines-11-01682-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/ad03a369d804/vaccines-11-01682-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/3eb40aa42788/vaccines-11-01682-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/91c70a5dad4c/vaccines-11-01682-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/1045d8e722d5/vaccines-11-01682-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/668765f5a161/vaccines-11-01682-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/412c2a0c228f/vaccines-11-01682-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/cc99b7f4a949/vaccines-11-01682-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/ad03a369d804/vaccines-11-01682-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/3eb40aa42788/vaccines-11-01682-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/91c70a5dad4c/vaccines-11-01682-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/1045d8e722d5/vaccines-11-01682-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca99/10674175/668765f5a161/vaccines-11-01682-g007.jpg

相似文献

1
Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates.TNX-1800（一种活病毒重组痘病毒候选疫苗）在非人灵长类动物中针对新冠病毒攻击的免疫原性和效力
Vaccines (Basel). 2023 Nov 2;11(11):1682. doi: 10.3390/vaccines11111682.
2
Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits.新型冠状病毒 TNX-1800 活重组痘病毒候选疫苗在叙利亚仓鼠和新西兰白兔中的免疫原性和耐受性。
Viruses. 2023 Oct 21;15(10):2131. doi: 10.3390/v15102131.
3
Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge.单次接种重组嵌合马痘病毒（TNX-801）疫苗可保护猕猴免受致命猴痘病毒挑战。
Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356.
4
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.SARS-CoV-2 重组 S 蛋白疫苗 S-268019-b 在食蟹猴中的免疫原性和保护效力。
Vaccine. 2022 Jul 29;40(31):4231-4241. doi: 10.1016/j.vaccine.2022.05.081. Epub 2022 Jun 6.
5
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.佐剂 SARS-CoV-2 受体结合域纳米颗粒疫苗在猕猴中的有效性和广度
bioRxiv. 2021 Apr 10:2021.04.09.439166. doi: 10.1101/2021.04.09.439166.
6
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.接种 SARS-CoV-2 刺突蛋白疫苗产生的保护性抗体在非人灵长类动物挑战后在肺部增强。
Sci Transl Med. 2021 Aug 18;13(607). doi: 10.1126/scitranslmed.abi4547. Epub 2021 Jul 27.
7
Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.在非人类灵长类动物中鉴定 COVID-19 mRNA 脂质纳米颗粒疫苗 Iribovax® 的稳定性、安全性和免疫原性。
J Control Release. 2023 Aug;360:316-334. doi: 10.1016/j.jconrel.2023.06.025. Epub 2023 Jul 5.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
10
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白中的E484K突变会降低但不会消除人类康复期和接种疫苗后血清的中和活性。
medRxiv. 2021 Jan 29:2021.01.26.21250543. doi: 10.1101/2021.01.26.21250543.

引用本文的文献

1
Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both and models.重组嵌合马痘病毒（TNX - 801）在小鼠和兔模型中相对于痘苗病毒株均减毒。
mSphere. 2024 Dec 19;9(12):e0026524. doi: 10.1128/msphere.00265-24. Epub 2024 Nov 13.
2
Immunization against Medically Important Human Coronaviruses of Public Health Concern.针对具有公共卫生重要性的医学相关人类冠状病毒的免疫接种。
Can J Infect Dis Med Microbiol. 2024 Jun 8;2024:9952803. doi: 10.1155/2024/9952803. eCollection 2024.
3
A Next-Generation Adenoviral Vaccine Elicits Mucosal and Systemic Immunogenicity and Reduces Viral Shedding after SARS-CoV-2 Challenge in Nonhuman Primates.

本文引用的文献

1
Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits.新型冠状病毒 TNX-1800 活重组痘病毒候选疫苗在叙利亚仓鼠和新西兰白兔中的免疫原性和耐受性。
Viruses. 2023 Oct 21;15(10):2131. doi: 10.3390/v15102131.
2
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus.天花疫苗的体液免疫持续时间及其与猴痘病毒的交叉反应。
Signal Transduct Target Ther. 2023 Sep 15;8(1):350. doi: 10.1038/s41392-023-01574-6.
3
Vaccination is the most effective and best way to avoid the disease of COVID-19.
一种新一代腺病毒疫苗在非人灵长类动物中引发黏膜和全身免疫原性，并减少了感染新冠病毒后的病毒脱落。
Vaccines (Basel). 2024 Jan 27;12(2):132. doi: 10.3390/vaccines12020132.
接种疫苗是避免感染 COVID-19 疾病最有效和最好的方法。
Immun Inflamm Dis. 2023 Aug;11(8):e946. doi: 10.1002/iid3.946.
4
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.高减毒痘病毒疫苗用于新发病毒性疾病。
J Mol Biol. 2023 Aug 1;435(15):168173. doi: 10.1016/j.jmb.2023.168173. Epub 2023 Jun 8.
5
Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.表达预融合稳定型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突糖蛋白的痘苗病毒株MVA在小鼠和仓鼠模型中诱导强大的保护作用并预防脑部感染。
Vaccines (Basel). 2023 May 21;11(5):1006. doi: 10.3390/vaccines11051006.
6
Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge.单次接种重组嵌合马痘病毒（TNX-801）疫苗可保护猕猴免受致命猴痘病毒挑战。
Viruses. 2023 Jan 26;15(2):356. doi: 10.3390/v15020356.
7
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.Ad26.COV2.S 的安全性、反应原性和免疫原性：在日本进行的一项 1 期、随机、双盲、安慰剂对照 COVID-19 疫苗试验结果。
Vaccine. 2023 Feb 24;41(9):1602-1610. doi: 10.1016/j.vaccine.2023.01.006. Epub 2023 Jan 5.
8
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.新型冠状病毒 2019 疫苗 NVX-CoV2373 在一项随机对照临床试验安慰剂对照阶段完成时的安全性和有效性。
Clin Infect Dis. 2023 Feb 8;76(3):398-407. doi: 10.1093/cid/ciac803.
9
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.2019冠状病毒病疫苗接种对发生长期新冠病毒病风险及现有长期新冠病毒病症状的影响：一项系统评价
EClinicalMedicine. 2022 Aug 27;53:101624. doi: 10.1016/j.eclinm.2022.101624. eCollection 2022 Nov.
10
The use of viral vectors in vaccine development.病毒载体在疫苗研发中的应用。
NPJ Vaccines. 2022 Jul 4;7(1):75. doi: 10.1038/s41541-022-00503-y.